Japan Said To Lack Infrastructure For Major Biotech Industry – Takeda President
This article was originally published in PharmAsia News
Executive Summary
Japan lacks the infrastructure and funding necessary to have a major biotechnology industry, according to the president of Takeda Pharmaceutical. Yasuchika Hasegawa said that moving beyond Japan's current status of limited biotech efforts requires more bioventure funds than the nation has and said the industry also is restricted by the current tax system and the lack of enough bio clusters. Japan's biotech ventures are characterized by their focus on just a few drugs or technologies in their pipelines, and Hasegawa said that moving beyond that would require being able to generate new revenue sources continually. (Click here for more - a subscription may be required
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.